The present technology relates to medical devices and methods. In particular, embodiments of the present disclosure are directed to surface treatments for accommodating intraocular lenses (hereinafter “AIOLs” or “AIOL” for singular).
Cataracts can affect a large percentage of the worldwide adult population with clouding of the native crystalline lens and resulting loss of vision. Patients with cataracts can be treated by native lens removal and surgical implantation of a synthetic intraocular lens (“IOL”). Worldwide, there are millions of IOL implantation procedures performed annually. In the U.S., there are 3.5 million cataract procedures performed, while worldwide there are over 20 million annual procedures performed.
Although IOL implantation procedures can be effective at restoring vision, conventional IOLs have several drawbacks. For example, many prior IOLs are not able to change focus as a natural lens would (known as accommodation). Other drawbacks of conventional IOLs include refractive errors that occur after implantation and require glasses for correcting distance vision, or in other cases the IOLs can be effective in providing good far vision but patients need glasses for intermediate and near vision.
AIOLs have been proposed to provide accommodative optical power for patients. In particular, AIOLs for use in the replacement of the native lens, within the lens capsule, allow the brain to control the natural focusing of an external image on the retina of the eye in the native fashion. AIOLs typically comprise a central optical portion and a peripheral non-optical portion. The optical portion is used to focus the image on the retina within the eye and the non-optical structural portion provides the support structure to hold the optical portion in place and the focusing or accommodating control mechanism which interfaces to the lens capsule. Native accommodation results from changing the focal length of the lens (natural or artificial in this case) within the lens capsule by tightening or relaxing the ciliary muscles, which connect to the perimeter of the capsule via the zonules. Hence the brain, via a control feedback loop and action on the ciliary muscles, controls the optical power of the AIOL to accommodate the distance of the object being focused on the retina.
However, prior AIOLs are generally still in development and have different drawbacks. For example, prior AIOLs can provide insufficient accommodation after implantation or produce suboptimal refractive correction of the eye. The amount of accommodation of the prior AIOLs can also decrease after implantation in at least some instances. The prior AIOLs can also be too large to be inserted through a small incision of the eye and may require the incision to be somewhat larger than would be ideal. Also, at least some of the prior AIOLs can be unstable when placed in the eye, which can lead to incorrect accommodation and other errors. Many prior AIOLs are also susceptible to internal reflections associated with non-optical portions of the AIOL structure scattering into the optical field of view—referred to as dysphotopsia. For purposes of this disclosure, all such internal reflections will be termed “dysphotopsia.”
Improved implantable intraocular lenses that accommodate with the natural mechanisms of controlling focusing of the eye that overcome at least some of the above deficiencies would be desirable. Ideally, such improved AIOLs would provide increased amounts of accommodation when implanted, provide refractive stability, introduce few if any perceptible visual artifacts, and allow the optical power of the eye to change from far vision to near vision in response to the distance of the object viewed by the patient.
Embodiments of the present disclosure provide improved AIOLs and methods for making and using AIOLs. In many embodiments, the AIOLs include accommodating structure comprising a substantially hydrophilic outer structure and a substantially hydrophobic fluid interior. The hydrophilic structure is expected to provide a stable and very compliant structure capable of controlled deformation via minimal forces sustainable by the focusing mechanisms of the native lens.
The hydrophobic fluid provides a high refractive index while minimizing osmotic effects. The high refractive index providing good optical power. The substantially hydrophilic structural material is typically made or fabricated from copolymers of acrylics, copolymers of hydrophilic acrylics and hydrophobic acrylics, or other optically transparent polymeric material. The hydrophilicity of the material will vary as a function of the relative proportion of hydrophilic and hydrophobic monomers which have been polymerized to create the materials.
In many embodiments, the hydrophilic outer structure is comprised of components that are machined from the hydrophilic materials in a relatively dry form, assembled in the dry form, the structure hydrated after assembly, the refractive oil introduced after hydration.
The machining step may leave portions of the surface with different degrees of roughness and/or hydrophilicity.
The substantially hydrophobic fluid interior is comprised a hydrophobic oil chosen but not limited to any of silicone, copolymers of silicone and hydrocarbon oils.
When AIOL is placed in the capsule bag (implanted), following a conventional cataract surgery, the AIOL comprising the substantially hydrophilic outer structure and a substantially hydrophobic fluid interior prevents the water from coalescing at the boundary surface defined as the interface of the hydrophilic material and the hydrophobic fluid. In another embodiment, the AIOL comprising the substantially hydrophilic outer structure and a substantially hydrophobic fluid interior, retards the water from coalescing at the boundary surface defined as the interface of the hydrophilic material and the hydrophobic fluid. However, in some instances water may coalesce at the boundary surface. Without being bound by any particular theory, it is believed the likelihood of water coalescence can increase as a function of surface roughness or surface irregularities of the hydrophilic structure at the boundary of the hydrophobic fluid and hydrophilic structure. Similarly, without being bound by any particular theory, it is believed the likelihood of water coalescence can increase with changes in the equilibrium moisture content of the hydrated hydrophilic structure with changes in temperature. Such temperature changes can occur when the AIOL is placed from its storage at room temperature to the temperature existing in the eye. Again, without being bound by any particular theory, it is believed the likelihood of water coalescence can increase with changes in internal to external pressure.
Over time, such coalesced water may be forced out of the inner chamber into the hydrophilic structure. In one embodiment, this process will be enhanced by a positive pressure gradient from the interior to the outer environment. In another embodiment, as the AIOL equilibrates over time, the hydrophobic fluid pushes the water back from the boundary surface into the more compatible hydrophilic outer structure which is surrounded by the hydrophilic environment existing in the eye and thus acts as a sink for additional moisture diffusing out.
In one possible scenario, neighboring coalesced water may form an agglomerate or water drops that may take longer to be driven out of the interior or the boundary surface in a reasonable amount of time. Such water drops can also negatively affect optical quality of the AIOL. Further, in some instances, water may form into droplets at the surface. Additionally, in some instances, these droplets may comprise a micelle. In one embodiment of the present technology, the possibility of water drops coalescing within the fluid interior or at the interface of the hydrophilic material and the hydrophobic fluid is reduced by providing a surface treatment to increase the hydrophobicity (i.e., decrease the surface energy) of the boundary surfaces thereby decreasing the “wettability” of these surfaces. In some embodiments, the present technology is expected to reduce the possibility of water drops coalescing within the fluid interior or at the interface of the hydrophilic material and the hydrophobic fluid by providing a surface treatment to increase the hydrophobicity of the boundary surfaces thereby making it more compatible to the hydrophobic fluid. In further embodiments, the present technology is expected to reduce the possibility of water drops coalescing within the fluid interior or at the interface of the hydrophilic material and the hydrophobic fluid by application or addition of hydrophobic surface treatment or hydrophobic coating that can adhere to hydrophilic material to retard or minimize or block the moisture diffusion to the interface between the of the hydrophilic material and the hydrophobic fluid.
In some embodiments, surface treatments in accordance with the present technology modify a boundary volume of the hydrophilic structural material at and adjacent the boundary surface to some depth into the structural material. In such embodiments, the relative proportion of hydrophobic to hydrophilic molecules and/or end or pendant groups is increased within this boundary volume. For purposes of this disclosure, the terms “molecules” and “end or pendant groups” are used interchangeably.
In some such embodiments the proportion of hydrophobic molecules within the volume after treatment varies as a function of depth. In such embodiments the proportion of hydrophobic molecules is greatest at the boundary surface and decreases deeper into the structural material. Although such a distribution or gradient in concentration is not strictly a coating, for purposes of this disclosure, “coating” will be used to describe both a material lying on top of another, and the formation of a gradient in molecular distribution in material adjacent a coated surface, or a combination of both.
When choosing a coating material, it will be appreciated that depending up on the proportion of hydrophilic material to hydrophobic material, swelling of the coating can vary from swelling of the base material upon hydration of both materials. Such differential swelling may cause internal stresses, strains, and or delamination which may be detrimental to the function of the AIOL.
In many of the embodiments described herein a treatment comprises applying a coating material, which comprises a solution of monomers (and/or in some instances oligomers), crosslinkers, and a catalyst to initiate crosslinking of the monomers. Although the treatments described herein typically increase the hydrophobicity of the surfaces or materials, such treatments and coating materials may be modified such that the hydrophilicity may be increased.
In other aspects of the present technology, the same or similar surface treatments are applied to the interior surfaces of the AIOL device to minimize to reduce the surface roughness of the machined surfaces. In another aspect of the present technology, the same or similar surface treatments are applied to the exterior surfaces of the AIOL device to minimize the migration of proteins into the AIOL structure and or the attachment of cells to the outer surface of the AIOL structure.
In another application of the materials and methods described herein, coatings may be used to modify the reflective characteristics at or near the surfaces of the structures comprising the AIOL. Such materials and methods can provide for reductions and or elimination of light delivered to the retina which has been captured by and or transmitted through non-optical portions of the AIOL system and or result from multiple internal reflections. Such light often results from internal reflections associated with non-optical portions of the AIOL structure. Such treatments will reduce and or eliminate the occurrence of dysphotopsia resulting from such internal reflections associated with AIOL implantation.
Features of the present technology are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present technology will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:
The present disclosure is directed to surface treatments for AIOLs and associated systems, methods, and devices. AIOLs, as described herein, are typically fabricated from dry hydrophilic components, which are hydrated prior to incorporating the substantially hydrophobic fluid interior into the assembly and the resulting assembly is kept in a hydrated state after manufacture. The surface treatments described herein will typically be applied to the dry pre-hydrated components or assemblies. In other embodiments, however, the surface treatments described herein may be applied to the components or assemblies in a fully hydrated state to take advantage of higher surface area (accessible in the hydrated state). In some instances, surfaces that are not to be treated can be masked. In other instances, the treatment may be applied without a mask.
AIOLs, as described herein, typically comprise a central optical structure comprised of at least one deformable optical component (e.g., an optical element) spaced apart along an optical axis, such as by a support structure concentric with the optical axis of the lenses. Several embodiments include a first optical component and a second optical component, and at least one of the first and second optical components can be deformable while the other of the first and second optical components can be deformable or rigid. The volume bounded by the first and second optical components, and optionally the lens support structure, may define a fluid chamber or fluid reservoir that can be filled with an ionic solution, such as saline, or non-ionic solutions such as dextran or silicone oil. In some embodiments of the AIOLs described herein, the AIOL components are machined from a dry pre-hydrated hydrophilic material. The machined components are then assembled such that the assembled AIOL comprises an outer surface, and an inner volume bounded by an inner surface. The inner volume is then filled by a hydrophobic optical fluid after the assembled device is hydrated. In some embodiments, the surface treatment is expected to decrease the roughness of the machined surfaces of the boundary surfaces and thereby reduce the mass of water coalescing at the boundary surface.
In other embodiments described herein, suitable coatings may be used to minimize dysphotopsia. Such coatings may comprise, for example, agents that minimize the amount of light transmitted through the coating. Transmission may be modified by increasing the scattering of light at the surface of the coating or within the coating, reflecting and or absorbing the light at the surface of or within the coating, or some combination. Such light interactions can be effected by the incorporation of particles within the coating material. A non-exhaustive list of a few such additive materials are opaque particles such as TiO2, gas bubbles, and water-soluble (or other solvent soluble) particles such as sugars or salts.
The hydrophilic acrylics described herein may include copolymers of both hydrophilic and hydrophobic components. The following is a partial list of some such component materials: 2-Hydroxyethyl methacrylate (HEMA), 2-Ethoxyethyl methacrylate (EOEMA), Ethylene glycol dimethylacrylate (EGDMA), polymethyl methacrylate (PMMA), Butyl acrylate, Hexyl acrylate and Hexafluoroisopropyl acrylate.
One suitable hydrophilic copolymer acrylic from which AIOLs described herein may be fabricated is a copolymer of HEMA and EOEMA. Such a material is BENZ IOL 25 UVX which may be purchased from Benz Research & Development, 6447 Parkland Dr., Sarasota, Fla. 34243 United States.
In some embodiments, surface treatments are aimed at minimizing, retarding or preventing water coalescence, and will be applied to the boundary surfaces described as the interface of the hydrophilic material and the hydrophobic fluid.
Treatments applied to the exterior surfaces of the AIOL to minimize migration of organic molecules or proteins typically comprise a smaller increase in hydrophobicity or a smaller reduction in hydrophilicity or a smaller reduction in surface energy than those applied to the inner boundary surfaces of the chamber surrounding the substantially hydrophobic fluid.
The nature and amount of surface treatment applied in accordance with the present technology can be controlled. In one embodiment, for example, the surface treatments will slightly decrease the surface energy and slightly increase the surface hydrophobicity of the hydrophilic material. In another embodiment, the surface treatments will decrease the surface energy and increase the surface hydrophobicity of the hydrophilic material. In still another embodiment, the surface treatments will substantially decrease the surface energy and substantially increase the surface hydrophobicity of the hydrophilic material.
In some embodiments, hydrophobicity is achieved by treating the boundary surfaces, or portions of the boundary surfaces, with surface treatment agents which comprise a portion to affix to the hydrophilic material while presenting another hydrophobic portion to the interior of the chamber surrounding the substantially hydrophobic fluid. The hydrophobic portions applied to the boundary surfaces may have different chemical compositions and different degree of hydrophobicity than those applied to the interior of the chamber surrounding the substantially hydrophobic fluid.
In some such treatments, a molecule with a hydrophobic end group can be chemically affixed to the surface of interest such that the hydrophobic end group is presented to the exterior. Chemically affixed may include either covalently bonds, hydrogen bonds, or chemical crosslinking. In another such surface treatments, a hydrophobic molecule can be covalently bonded, chemically crosslinked, or adhered by hydrogen bonding to the surface of interest. For chemical cross-linking, biocompatible cross linkers such as amines, trifunctional or multifunctional hydroxyl compound, glycerin, acrylics and Ethylene glycol dimethacrylate [EGDMA] can be used.
The application area of the surface treatment can be continuous, semi-continuous or in separate patches. In an alternative treatment for use with copolymers comprised of hydrophilic and hydrophobic constituents, a surface treatment may be applied which preferentially etches the hydrophilic portions while leaving intact the hydrophobic portions.
In yet another alternative the surface treatment comprises applying a layer of copolymer to the surface of interest which has a much lower hydrophilicity or a much lower saturation water content than the AIOL assembly or outer structure material. Alternatively, or in combination, the surface treatment substantially covers the channels or passages in the outer structure material in order to prevent or resist the diffusion of moisture through the surface layer in the hydrated use state of the outer structure material. In some such embodiments, the copolymer may contain the same constituents as the hydrophilic base material being coated but in different proportions of hydrophilic acrylics and hydrophobic acrylics. In one embodiment, the surface treatment comprises at least 50% of the hydrophobic acrylics by weight. In another embodiment, the surface treatment comprises at least 70% of the hydrophobic acrylics by weight. In another embodiment, the surface treatment comprises at least 90% of the hydrophobic acrylics by weight. In some embodiments, the surface treatment comprises a thin coating of material of the same surface energy as the structure applied in such a fashion as to reduce the roughness of the surfaces resultant from the manufacturing processes.
The surface treatments can be delivered by various methods such as brush coating, spray coating, dip coating, vapor deposition, plasma deposition or their combinations thereof. In embodiments in which the coating material is delivered in a solvent, useful biocompatible solvents include but not limited to NMP, DMSO, TCE, ethyl acetate, THF, DMF and DMAC.
In one embodiment, the surface of interest may undergo one surface treatment. In another embodiment, the surface of interest may undergo two surface treatments. In yet another embodiment, the surface of interest may undergo more than two surface treatments.
In some instances, the surfaces to be treated will be prepared or pretreated by surface modifications or surface activation such as treatments by; UV exposure, plasma, corona discharge, alcohol etching solvent cleaning and acidic etching.
In some instances, the surfaces to be treated will be prepared by surface modifications or surface activation such as treatments which replace OH groups with other groups which render the surface less hydrophilic.
Materials comprised in the surface treatments may be selected from, but are not limited to, any of the following: Silicone, Polyurethane, and Acrylic.
In one embodiment, the silicone for the surface treatment comprises a linear silicone polymer. In another embodiment, the silicone for the surface treatment comprises a cross-linked silicone polymer.
In one embodiment, the polyurethane for the surface treatment comprises an aromatic hard segment. In another embodiment, the polyurethane for the surface treatment comprises an aliphatic hard segment. In still other embodiments, the polyurethane for the surface treatment may comprise hydrophobic polyurethanes such as polycarbonate polyurethane, poly(carbonate-co-siloxane) polyurethane, polysiloxane polyurethane, polyether polyurethane, poly(ether-co-carbonate) polyurethane, or poly(ether-co-siloxane), a linear urethane polymer, and/or a cross-linked urethane polymer.
In one embodiment, the acrylic comprises a hydrophobic acrylic. In another embodiment, the acrylic comprises a copolymer of hydrophilic acrylics and hydrophobic acrylics. Exemplary hydrophilic acrylics include but are not limited to 2-Hydroxyethyl methacrylate (HEMA). Exemplary hydrophobic acrylics include but are not limited to 2-Ethoxyethyl methacrylate (EOEMA), polymethyl methacrylate (PMMA), Butyl acrylate, Hexyl acrylate and Hexafluoroisopropyl acrylate. In one embodiment, the acrylic comprises a crosslinker. In one embodiment, the acrylic comprises a cross-linked acrylic polymer.
The average thickness of surface treatment is less than 20 micrometers, preferably less than 10 micrometers and more preferably less than 2 micrometers. The surface treatment is substantially chemical compatible with the hydrophilic outer structure leading to better adhesion with the hydrophilic outer structure. The surface treatment will not degrade or disintegrate in aqueous environment and is hydrolytically stable. The surface treatment is ductile and optically clear so it will not interfere with functioning of the AIOL. The surface treatment is biocompatible.
Several possible Acrylic-based recipes are presented in Table A and Table B below. Several more possible treatment material recipes and procedures are listed in the Examples below.
Coatings described herein may be applied by any suitable means including, for example, painting, spraying, vapor deposition processes, and/or application via a mist chamber. One useful application method comprises subjecting the surface and adjacent volume of structural material to a volume of the unpolymerized formula or partially polymerized (comprised of oligomers) formula. The time between the application of the treatment and the initiation (or re-initiation) of polymerization, treatment time, may be varied for any of the treatment methods. The treatment time will affect the depth of penetration of the monomers and multimers comprising the coating material prior to polymerization. The volume of coating material will be greater closer to the application surface and decrease as the distance from the coating surface increases.
The first component 110 includes a first inner surface 111 having one or more inner surface regions defining various portions of the first component 110. In the illustrated embodiment, for example, the first component 110 includes a first inner surface region 111a and a second inner surface region 111b. The second component 120 also comprises a second inner surface 121 having one or more inner surface regions defining various portions of the second component. For example, the second component 120 includes a third inner surface region 121a and a fourth inner surface regions 121b. In the embodiment shown in
The AIOL 100 has a fluid accommodating lens 112 defined by a fluid chamber or reservoir 130 bounded between a first optical component 132 and a second optical component 134. The first and second optical components 132 and 134 may be planar members (e.g., optical membranes) of the first and second components 110 and 120, respectively. The first and second optical components 132 and 134, for example, can be integrally formed as optical membranes with the other portions of the first and second components 110 and 120. In alternate embodiments, either or both of the membranes of the first and second optical components 132 and 134 may be a lens (i.e., have an optical power).
The fluid chamber 130 is in fluid communication with the bellows region 140 to transfer fluid (e.g., the hydrophobic fluid) between the fluid chamber 130 and the bellows region 140 in response to shape changes of the lens capsule to provide optical power changes to the accommodating intraocular lens. In some embodiments, for example, the fluid chamber 130 and the bellows region 140 may be filled with a substantially hydrophobic fluid that is transferred therebetween.
Referring to
As noted previously, the AIOL 100 may include a surface treatment on various portions of one or more components of the AIOL 100. In some embodiments, for example, portions of inner surfaces 111 and 121 surrounding the bellows region 140 may be treated to reduce the surface energy or increase the surface hydrophobicity. In some embodiments, some or all of the mating surfaces are left untreated. In alternate embodiments, all of inner surfaces (including inner surfaces 111 and 121) are treated to reduce their surface energy or increase the surface hydrophobicity.
In some embodiments, only selected portions of inner surfaces 111 and 121 are treated to reduce, prevent or resist the diffusion of moisture through the surface layer. In alternate embodiments, all or substantially all of inner surfaces 111 and 121 are treated to resist the diffusion of moisture through the surface layer in the hydrated use state of the outer structure material.
In some embodiments, only the portions of outer surface 113 surrounding the fluid accommodating region 112 may be treated to reduce the surface energy and/or reduce prevent or resist the diffusion of moisture through the surface layer. In alternate embodiments, all of outer surfaces 113 and 123 can be treated to reduce their surface energy, reduce the pore size of the surface layer, and/or increase the surface hydrophobicity.
In some embodiments, a surface treatment that resists the diffusion of moisture through the surface comprises substantially covering the channels or passages in the outer structure material of the AIOL 100 to prevent or resists the diffusion of moisture through the surface.
Suitable surface treatments for use with the AIOL 100 of
In an alternate procedure, the first and second components 110 and 120 can be filled with a coating material and the coating material is allowed to diffuse into the structural material for a period of time between 1 minute 1 day, more preferably between 5 minutes and 20 minutes prior to the initiation of polymerization. In certain embodiments, selected surfaces of the first component 110 and second component 120 (e.g., the bond joints 104, 105, 106 and/or other selected surfaces) may be masked.
As best seen in
1. Coating composition
2. Coating methods
3. Coating initiation methods
4. High viscosity solutions
5. Coating expected outcomes
6. Measurements methods
7. Methods
A mixture containing xx gm of 2-HEMA, yy gm of EOEMA, zz gm of 2,2-azobis (2,4 dimethyl valeronitrile) and 0.3% by weight (of total mixture weight) of ethylene glycol dimethacrylate (EGDMA) were prepared in a clean vial. The mixture was thoroughly mixed using a magnetic stirrer making sure that there were no undissolved solid particles and there were no schlerian lines visible. The mixture was later filtered in a clean room through a 0.2 microns filter to remove any possible floating particles etc.
The samples of the lens parts to be coated were prepared. The side to be coated was exposed and other areas were protected from contact with the coating agents. The parts to be coated were dipped in the mixture from Table 1 for about 1-60 seconds and removed making sure that a film of the coating mixture was deposited. The lens was placed in an oven at 60° C. to cure for about 18 hours. Characterize by FTIR-ATR, contact angle(s) values and EDX.
The exact formulations with values of xx, yy, zz are shown in Table 1.
A mixture containing xx gm of 2-HEMA, yy gm of EOEMA, zz gm of 2,2-azobis (2,4 dimethyl valeronitrile) and 0.3% by weight (of total mixture weight) of ethylene glycol dimethacrylate (EGDMA) were prepared in a clean vial. The mixture was thoroughly mixed using a magnetic stirrer making sure that there were no undissolved solid particles and there were no schlerian lines visible. The mixture was later filtered in a clean room through a 0.2 microns filter to remove any possible floating particles, etc.
The samples of the lens parts to be coated were prepared. The side to be coated was exposed and all other areas were protected from contact with coating agents. The parts to be coated were dipped in the mixture from Table 1 for about 1-60 seconds and removed making sure that a film of the coating mixture was deposited. The lens was treated with a UV medium pressure mercury lamp with light emitting at a wavelength of >350 nm for about 2-6 minutes. The lamp was turned off and the parts were removed. Characterize by FTIR-ATR, contact angles values and EDX.
The exact formulations with values of xx, yy, zz are shown in Table 1.
A mixture containing xx gm of 2-HEMA, yy gm of EOEMA, zz gm of Esperox 33 (tert-Butyl peroxyneodecanoate, from Akzo Nobel Industries) and 0.3% by weight (of total mixture weight) of ethylene glycol dimethacrylate (EGDMA) were prepared in a clean vial. The mixture was thoroughly mixed using a magnetic stirrer making sure that there were no undissolved solid particles and there were no schlerian lines visible. The mixture was later filtered in a clean room through 0.2 microns filter to remove any possible floating particles etc.
The samples of the lens parts to be coated were prepared. The side to be coated was exposed and all other areas were protected from contact with the coating agents. The parts to be coated were dipped in the above mixture from Table 2 for about 1-60 seconds and removed making sure that a film of the coating mixture was deposited. The lens was placed in an oven at 40° C. to cure for about 18 hours. Characterize by FTIR-ATR, contact angle(s) values and EDX.
The exact formulations with values of xx, yy, zz are shown in Table 2 below.
A mixture containing xx gm of 1,1,1,3,3,3-Hexafluoroisopropyl acrylate (gm), yy gm of Butyl acrylate (gm), and/or xy gm of 4-Hydroxybutyl acrylate (gm) zz gm of 2,2-azobis (2,4 dimethyl valeronitrile) and 0.3% by weight (of total mixture weight) of ethylene glycol dimethacrylate (EGDMA) was prepared in a clean vial. The mixture was thoroughly mixed using a magnetic stirrer making sure that there were no undissolved solid particles and there were no schlerian lines visible. The mixture was later filtered in a clean room through a 0.2 microns filter to remove any possible floating particles etc.
The samples of the lens parts to be coated were prepared. The side to be coated was exposed and all other areas were protected from contact with coating agents. The parts to be coated were dipped in the above mixture from Table 3 for about 1-60 seconds and removed making sure that a film of the coating mixture was deposited. The lens was treated with a UV medium pressure mercury lamp with light emitting at a wavelength of >350 nm for about 2-6 minutes. The lamp was turned off and the parts were removed. Characterize by FTIR-ATR, contact angle(s) values and EDX.
The exact formulations with values of xx, yy, xy, zz are shown in Table 3.
A mixture containing xx gm of 1,1,1,3,3,3-Hexafluoroisopropyl acrylate (gm), yy gm of Butyl acrylate (gm), and/or xy gm of 4-hydroxybutyl acrylate (gm) zz gm of 2,2-azobis (2,4 dimethyl valeronitrile) and 0.3% by weight (of total mixture weight) of ethylene glycol dimethacrylate (EGDMA) was prepared in a clean vial. The mixture was thoroughly mixed using a magnetic stirrer making sure that there were no undissolved solid particles and there were no schlerian lines visible. The mixture was later filtered in a clean room through 0.2 microns filter to remove any possible floating particles etc.
The samples of the lens parts to be coated were prepared. The side to be coated was exposed and all other areas were protected from contact with the coating agents. The parts to be coated were dipped in the above mixture from Table 3 for about 1-60 seconds and removed making sure that a film of the coating mixture was deposited. The lens was placed in an oven at 60° C. to cure for about 18 hours. Characterize by FTIR-ATR, contact angle(s) values and EDX.
The exact formulations with values of xx, yy, xy, zz are shown in Table 3.
A mixture containing xx gm of 1,1,1,3,3,3-Hexafluoroisopropyl acrylate (gm), yy gm of Butyl acrylate (gm), and/or xy gm of 4-hydroxybutyl acrylate (gm) zz gm of Esperox 33 (tert-Butyl peroxyneodecanoate) and 0.3% by weight (of total mixture weight) of ethylene glycol dimethacrylate (EGDMA) was prepared in a clean vial. The mixture was thoroughly mixed using a magnetic stirrer making sure that there were no undissolved solid particles and there were no schlerian lines visible. The mixture was later filtered in a clean room through 0.2 microns filter to remove any possible floating particles etc.
The samples of the lens parts to be coated were prepared. The side to be coated was exposed and all other areas were protected from contact with the coating agents. The parts to be coated were dipped in the above mixture from Table 3 for about 1-60 seconds and removed making sure that a film of the coating mixture was deposited. The lens was placed in an oven at 40° C. to cure for about 18 hours. Characterize by FTIR-ATR, contact angle(s) values and EDX.
The exact formulations with values of xx, yy, xy, zz are shown in Table 4.
A 95% ethanol in water solution was mixed with about 2 ml acetic acid and the pH was measured to be 4.5-5.5. The temperature was maintained to ambient (20° C.). The pH was adjusted if necessary to remain in the range of 4.5-5.5. A 2.0 ml solution of octyltriethoxysilane was measured in a hood and was added to the liquid slowly. The total time from the start of mixing the octyltriethoxysilane was 5 minutes.
In a separate process, the lens parts to be coated were prepared. The side to be coated was exposed and all other areas were protected from contact with coating agents. The parts to be coated were brought in contact with the above mixture for about 60-90 seconds. The parts were removed after 90 seconds and allowed to cure for about 24 hours at room temperature or 6-8 hours at 60° C. in an oven.
Characterize by FTIR-ATR, contact angle(s) values and EDX.
A mixture containing xx gm of 2-HEMA, yy gm of EOEMA, zz gm of 2,2-azobis (2,4 dimethyl valeronitrile) and 0.3% by weight (of total mixture weight) of ethylene glycol dimethacrylate (EGDMA) was prepared in a clean vial per Table 1. The total volume of the mixture was adjusted to about 30 ml. The mixture was placed in a 40 ml glass vial. A magnetic stirrer was placed inside the mixture and was heated to 80-90° C. for about 8-10 minutes. The monomer solution was monitored closely. When the vortex created by the stir-bar completely disappeared (e.g. the surface of the liquid was completely flat), the monomer was removed quickly from the stir plate and was placed in the ice water. The monomer was agitated horizontally until it cooled completely.
The samples of the lens parts to be coated were prepared. The side to be coated was exposed and all other areas were protected from contact with the coating agents. The parts to be coated were dipped in the above mixture or the viscous solution was painted over it. The lens was treated with a UV medium pressure mercury lamp with light emitting at a wavelength of >350 nm for about 2-6 minutes. The lamp was turned off and the parts were removed.
Characterize by FTIR-ATR, contact angle(s) values and EDX.
The exact formulations with values of xx, yy, xy, zz are shown in Table 1.
A mixture containing xx gm of 2-HEMA, yy gm of EOEMA, zz gm of 2,2-azobis (2,4 dimethyl valeronitrile) and 0.3% by weight (of total mixture weight) of ethylene glycol dimethacrylate (EGDMA) was prepared in a clean vial per Table 1. The total volume of the mixture was adjusted to about 30 ml. The mixture was placed in a 40 ml glass vial. A magnetic stirrer was placed inside the mixture and was heated to 80-90° C. for about 8-10 minutes. The monomer solution was monitored closely. When the vortex created by the stir-bar completely disappeared (e.g. the surface of the liquid was completely flat), the monomer was removed quickly from the stir plate and was placed in the ice water. The monomer was agitated horizontally until it cooled completely.
The samples of the lens parts to be coated were prepared. The side to be coated was exposed and all other areas were protected from contact with coating agents. The parts to be coated were dipped in the above mixture or the viscous solution was painted over it. The coated parts were placed at 60° C. in an oven for a minimum of 18 hours.
Characterize by FTIR-ATR, contact angle(s) values and EDX.
The exact formulations with values of xx, yy, zz are shown in Table 1.
A mixture containing xx gm of 2-HEMA, yy gm of EOEMA, zz gm of Esperox 33 (tert-Butyl peroxyneodecanoate and 0.3% by weight (of total mixture weight) of ethylene glycol dimethacrylate (EGDMA) was prepared in a clean vial per Table 1. The total volume of the mixture was adjusted to about 30 ml. The mixture was placed in a 40 ml glass vial. A magnetic stirrer was placed inside the mixture and was heated to 80-90° C. for about 8-10 minutes. The monomer solution was monitored closely. When the vortex created by the stir-bar completely disappeared (e.g. the surface of the liquid was completely flat), the monomer was removed quickly from the stir plate and was placed in the ice water. The monomer was agitated horizontally until it cooled completely.
The samples of the lens parts to be coated were prepared. The side to be coated was exposed and all other areas were protected from contact with the coating agents. The parts to be coated were dipped in the above mixture or the viscous solution was painted over it. The coated parts were placed at 40° C. in an oven for a minimum of 18 hours.
Characterize by FTIR-ATR, contact angle(s) values and EDX.
The exact formulations with values of xx, yy, zz are shown in Table 2.
The samples of the lens parts to be coated were prepared. The side to be coated was exposed and all other areas were protected from contact with coating agents. The coating was applied at a vendor site. Basically, the solid dimer was heated under vacuum and vaporized into a dimeric gas. The gas was then pyrolized to cleave the dimer to its monomeric form.
In the room temperature deposition chamber, the monomer gas was deposited on all surfaces as a thin, transparent polymer film.
Characterize by FTIR-ATR, contact angle(s) values and EDX.
A mixture containing xx gm of 2-HEMA, yy gm of EOEMA, zz gm of 2,2-azobis (2,4 dimethyl valeronitrile) and 0.3% by weight (of total mixture weight) of ethylene glycol dimethacrylate (EGDMA) were prepared in a clean vial. The mixture was thoroughly mixed using a magnetic stirrer making sure that there were no undissolved solid particles and there were no schlerian lines visible. The mixture is heated (at 90° C.) and stirred to form oligomers. The process is terminated when the viscosity is at a selected level (e.g., approximately 150-250 cps, approximately 200 cps), and the mixture is then cooled to stop the reaction. The resulting mixture is then stored for use.
The mixture can be dispensed on selected surface(s) for treatment via a digital syringe or any of the methods disclosed herein. The treated surfaces are post treated by allowing them to sit for 30 minutes at room temperature, and then at 40° C. for 18 hours under argon.
Features Key—Figures
Below are the key codes for the features specified in the figures described herein. Particular figure features are numbered using the figure number preceding one of the codes listed below. For example, the feature number for the AIOL of
Several aspects of the present technology are set forth in the following examples.
1. An accommodating intraocular lens system, comprising:
2. The accommodating intraocular lens system of example 1 wherein the treated surfaces comprise the same proportion of hydrophobic and hydrophilic elements as the base material.
3. The accommodating intraocular lens system of example 1 wherein the treated surfaces comprise a proportion of approximately 25% 2-Hydroxyethyl methacrylate (HEMA) elements to approximately 75% hydrophobic elements.
4. The accommodating intraocular lens system of any one of examples 1-3 wherein an inner surface defining, at least in part, the inner fluid chamber includes the surface treatment.
5. The accommodating intraocular lens system of any one of examples 1-4 wherein the accommodating structure comprises an outer surface defined, at least in part, by a periphery of the first component and the second component, and wherein at least a portion of the outer surface includes the surface treatment.
6. The accommodating intraocular lens system of any one of examples 1-5 wherein the surface treatment comprises a coating applied to the corresponding one or more surfaces of the accommodating structure.
7. The accommodating intraocular lens system of example 1 wherein the surface treatment is adapted to reduce the density of hydrophilic end groups from the treated region.
8. The accommodating intraocular lens system of example 1 wherein the surface treatment is adapted to mask hydrophilic end groups from the treated region.
9. The accommodating intraocular lens system of any one of examples 1-8 wherein the outer fluid chamber is around at least a portion of the inner fluid chamber and configured to interface with a native eye capsule of a human subject such that fluid flows between the outer fluid chamber and the inner fluid chamber to move the first optical element for providing accommodation.
10. The accommodating intraocular lens system of any one of examples 1-9, further comprising fluid within the inner fluid chamber, wherein the fluid comprises a hydrophobic liquid.
11. The accommodating intraocular lens system of any one of examples 1-10 wherein the first and second components are bonded to one another.
12. The accommodating intraocular lens system of any one of examples 1-11 wherein the first and second components are bonded to one another at one or more bond sites, and wherein the one or more bond sites do not include the surface treatment.
13. The accommodating intraocular lens system of any one of examples 1-12 wherein the first and second components are sufficiently flexible to be folded into a reduced cross-section delivery configuration.
14. An accommodating intraocular lens system for implantation within a lens capsule of a subject, comprising:
15. The accommodating intraocular lens system of example 14 wherein the hydrophilic outer surface of the accommodating structure is composed of a first material, and wherein the coating comprises a prepolymer of the first material.
16. The accommodating intraocular lens system of example 15 wherein first material comprises a copolymer of 2-Hydroxyethyl methacrylate (HEMA) and 2-Ethoxyethyl methacrylate (EOEMA)
17. The accommodating intraocular lens system of example 15 wherein the coating comprises EOEMA.
18. The accommodating intraocular lens system of any one of examples 14-17 wherein the coating reduces surface roughness of the treated regions as compared with untreated regions of the first and second optical components.
19. The accommodating intraocular lens system of example 14 wherein the coating increases hydrophobicity of the treated regions as compared to untreated regions.
20. An accommodating intraocular lens for placement within a lens capsule of a subject, the accommodating intraocular lens comprising:
21. An accommodating intraocular lens for placement within a lens capsule of a subject, the accommodating intraocular lens comprising a generally hydrophilic surface, and wherein the accommodating intraocular lens includes a coating on at least a portion of the surface, and further wherein the coated regions of the surface of the accommodating intraocular lens are more hydrophobic than untreated regions of the surface.
The above detailed description of embodiments of the technology are not intended to be exhaustive or to limit the technology to the precise form disclosed above. Although specific embodiments of, and examples for, the technology are described above for illustrative purposes, various equivalent modifications are possible within the scope of the technology as those skilled in the relevant art will recognize. For example, any of the features of the intraocular lens systems described herein may be combined with any of the features of the other intraocular lenses described herein and vice versa. Moreover, although steps are presented in a given order, alternative embodiments may perform steps in a different order. The various embodiments described herein may also be combined to provide further embodiments.
From the foregoing, it will be appreciated that specific embodiments of the technology have been described herein for purposes of illustration, but well-known structures and functions have not been shown or described in detail to avoid unnecessarily obscuring the description of the embodiments of the technology. Where the context permits, singular or plural terms may also include the plural or singular term, respectively.
Moreover, unless the word “or” is expressly limited to mean only a single item exclusive from the other items in reference to a list of two or more items, then the use of “or” in such a list is to be interpreted as including (a) any single item in the list, (b) all of the items in the list, or (c) any combination of the items in the list. Additionally, the term “comprising” is used throughout to mean including at least the recited feature(s) such that any greater number of the same feature and/or additional types of other features are not precluded. It will also be appreciated that specific embodiments have been described herein for purposes of illustration, but that various modifications may be made without deviating from the technology. Further, while advantages associated with some embodiments of the technology have been described in the context of those embodiments, other embodiments may also exhibit such advantages, and not all embodiments need necessarily exhibit such advantages to fall within the scope of the technology. Accordingly, the disclosure and associated technology can encompass other embodiments not expressly shown or described herein.
This application is a 35 U.S.C. § 371 U.S. National Phase application of International Patent Application No. PCT/US2018/034858, filed May 29, 2018, and entitled SURFACE TREATMENTS FOR ACCOMMODATING INTRAOCULAR LENSES AND ASSOCIATED METHODS AND DEVICES, which claims priority to U.S. Provisional Application Nos. 62/512,536, filed May 30, 2017, and titled SURFACE TREATMENTS FOR HYDROPHILIC AIOL, and 62/560,527, filed Sep. 19, 2017, and titled SURFACE TREATMENTS FOR HYDROPHILIC AIOL. The contents of each of the above applications are incorporated herein by reference in their entireties.
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/US2018/034858 | 5/29/2018 | WO | 00 |
Publishing Document | Publishing Date | Country | Kind |
---|---|---|---|
WO2018/222579 | 12/6/2018 | WO | A |
Number | Name | Date | Kind |
---|---|---|---|
4440918 | Rice et al. | Apr 1984 | A |
4663409 | Friends et al. | May 1987 | A |
4709996 | Michelson et al. | Dec 1987 | A |
4731078 | Stoy et al. | Mar 1988 | A |
4731080 | Galin | Mar 1988 | A |
4842601 | Smith et al. | Jun 1989 | A |
4892543 | Turley | Jan 1990 | A |
4932966 | McMaster et al. | Jun 1990 | A |
5074942 | Orlosky et al. | Dec 1991 | A |
5211662 | Barrett et al. | May 1993 | A |
5217491 | Vanderbilt | Jun 1993 | A |
5405386 | Rheinish et al. | Apr 1995 | A |
5423929 | Grisoni et al. | Jun 1995 | A |
5489302 | Skottun | Feb 1996 | A |
5556929 | Yokoyama et al. | Sep 1996 | A |
5612391 | Chabrecek et al. | Mar 1997 | A |
5620720 | Glick et al. | Apr 1997 | A |
5807944 | Hirt et al. | Sep 1998 | A |
5891931 | Leboeuf et al. | Apr 1999 | A |
5914355 | Kuenzler | Jun 1999 | A |
5944753 | Galin et al. | Aug 1999 | A |
5945465 | Ozark et al. | Aug 1999 | A |
5945498 | Lohmann et al. | Aug 1999 | A |
6140438 | Kawaguchi et al. | Oct 2000 | A |
6346594 | Watanabe et al. | Feb 2002 | B1 |
6447920 | Chabrecek et al. | Sep 2002 | B1 |
6465056 | Chabrecek et al. | Oct 2002 | B1 |
6521352 | Lohmann et al. | Feb 2003 | B1 |
6537316 | Chambers | Mar 2003 | B1 |
6558420 | Green et al. | May 2003 | B2 |
6582754 | Pasic et al. | Jun 2003 | B1 |
6586038 | Chabrecek et al. | Jul 2003 | B1 |
6630243 | Ozark et al. | Oct 2003 | B2 |
6660035 | Yaross et al. | Dec 2003 | B1 |
6685741 | Landreville et al. | Feb 2004 | B2 |
6713583 | Liao et al. | Mar 2004 | B2 |
6730123 | Klopotek et al. | May 2004 | B1 |
6734321 | Chabrecek et al. | May 2004 | B2 |
6747090 | Haitjema et al. | Jun 2004 | B2 |
6761737 | Ting et al. | Jul 2004 | B2 |
6764511 | Ting et al. | Jul 2004 | B2 |
6767363 | Green et al. | Jul 2004 | B1 |
6767979 | Muir et al. | Jul 2004 | B1 |
6786934 | Ting et al. | Sep 2004 | B2 |
6818017 | Shu et al. | Nov 2004 | B1 |
6818158 | Pham et al. | Nov 2004 | B2 |
6835410 | Chabrecek et al. | Dec 2004 | B2 |
6846326 | Nguyen et al. | Jan 2005 | B2 |
6858040 | Ting et al. | Feb 2005 | B2 |
6884261 | Zadno-Azizi et al. | Apr 2005 | B2 |
6893595 | Muir et al. | May 2005 | B1 |
6893685 | Pasic et al. | May 2005 | B2 |
6899732 | Zadno-Azizi et al. | May 2005 | B2 |
6935743 | Shadduck | Aug 2005 | B2 |
6969403 | Yang et al. | Nov 2005 | B2 |
7041134 | Ting et al. | May 2006 | B2 |
7087080 | Ting et al. | Aug 2006 | B2 |
7118596 | Ting et al. | Oct 2006 | B2 |
7198640 | Nguyen | Apr 2007 | B2 |
7217778 | Flipsen et al. | May 2007 | B2 |
7226478 | Ting et al. | Jun 2007 | B2 |
7416562 | Gross et al. | Aug 2008 | B2 |
7438723 | Esch | Oct 2008 | B2 |
7452378 | Ting et al. | Nov 2008 | B2 |
7468397 | Schorzman et al. | Dec 2008 | B2 |
7479530 | Chan et al. | Jan 2009 | B2 |
7557231 | Schorzman et al. | Jul 2009 | B2 |
7588334 | Matsushita et al. | Sep 2009 | B2 |
7591849 | Richardson et al. | Sep 2009 | B2 |
7601766 | Schorzman et al. | Oct 2009 | B2 |
7637947 | Scholl et al. | Dec 2009 | B2 |
7714090 | Iwamoto et al. | May 2010 | B2 |
7744603 | Zadno-Azizi et al. | Jun 2010 | B2 |
7744646 | Zadno-Azizi et al. | Jun 2010 | B2 |
7781558 | Schorzman et al. | Aug 2010 | B2 |
7806929 | Brown et al. | Oct 2010 | B2 |
7806930 | Brown et al. | Oct 2010 | B2 |
7842087 | Ben | Nov 2010 | B2 |
7883540 | Niwa et al. | Feb 2011 | B2 |
7906563 | Huang et al. | Mar 2011 | B2 |
7942929 | Linhardt et al. | May 2011 | B2 |
8003710 | Medina et al. | Aug 2011 | B2 |
8025823 | Figueroa et al. | Sep 2011 | B2 |
8034107 | Stenger et al. | Oct 2011 | B2 |
8048155 | Shadduck et al. | Nov 2011 | B2 |
8071703 | Zhou et al. | Dec 2011 | B2 |
8105623 | Schorzman et al. | Jan 2012 | B2 |
8158712 | Your | Apr 2012 | B2 |
8187325 | Zadno-Azizi et al. | May 2012 | B2 |
8211955 | Chang et al. | Jul 2012 | B2 |
8222360 | Liao | Jul 2012 | B2 |
8251509 | Zickler et al. | Aug 2012 | B2 |
8283429 | Zhou et al. | Oct 2012 | B2 |
8328869 | Burns et al. | Dec 2012 | B2 |
8357771 | Medina et al. | Jan 2013 | B2 |
8377123 | Zadno et al. | Feb 2013 | B2 |
8414646 | Gifford et al. | Apr 2013 | B2 |
8420711 | Awasthi et al. | Apr 2013 | B2 |
8425595 | Evans et al. | Apr 2013 | B2 |
8425599 | Shadduck et al. | Apr 2013 | B2 |
8425926 | Qiu et al. | Apr 2013 | B2 |
8430928 | Liao | Apr 2013 | B2 |
8454688 | Evans et al. | Jun 2013 | B2 |
8486142 | Bumbalough et al. | Jul 2013 | B2 |
8500806 | Phillips et al. | Aug 2013 | B1 |
8585758 | Woods | Nov 2013 | B2 |
8603166 | Park | Dec 2013 | B2 |
8609745 | Medina et al. | Dec 2013 | B2 |
8663510 | Graney et al. | Mar 2014 | B2 |
8680172 | Liao | Mar 2014 | B2 |
8728158 | Whitsett | May 2014 | B2 |
8759414 | Winter et al. | Jun 2014 | B2 |
8784485 | Evans et al. | Jul 2014 | B2 |
8827447 | Awasthi et al. | Sep 2014 | B2 |
8835525 | Chang et al. | Sep 2014 | B2 |
8851670 | Zickler et al. | Oct 2014 | B2 |
8863749 | Gooding et al. | Oct 2014 | B2 |
8877227 | Ravi | Nov 2014 | B2 |
8899745 | Domschke | Dec 2014 | B2 |
8900298 | Chazan et al. | Dec 2014 | B2 |
8956409 | Ben | Feb 2015 | B2 |
8968399 | Ghabra | Mar 2015 | B2 |
8992609 | Shadduck | Mar 2015 | B2 |
8993651 | Chang et al. | Mar 2015 | B2 |
9005492 | Chang et al. | Apr 2015 | B2 |
9005700 | Qiu et al. | Apr 2015 | B2 |
9006359 | Schultz et al. | Apr 2015 | B2 |
9011532 | Catlin et al. | Apr 2015 | B2 |
9023915 | Hu et al. | May 2015 | B2 |
9034035 | Assia et al. | May 2015 | B2 |
9039174 | Awasthi et al. | May 2015 | B2 |
9044302 | Gooding et al. | Jun 2015 | B2 |
9052439 | Samuel et al. | Jun 2015 | B2 |
9052440 | Chang et al. | Jun 2015 | B2 |
9095424 | Atkinson et al. | Aug 2015 | B2 |
9097840 | Chang et al. | Aug 2015 | B2 |
9125736 | Atkinson et al. | Sep 2015 | B2 |
9186244 | Rao et al. | Nov 2015 | B2 |
9198572 | Zickler et al. | Dec 2015 | B2 |
9254189 | Azar et al. | Feb 2016 | B2 |
9265604 | Woods | Feb 2016 | B2 |
9280000 | Simonov et al. | Mar 2016 | B2 |
9289287 | Atkinson et al. | Mar 2016 | B2 |
9326848 | Woods | May 2016 | B2 |
9364316 | Kahook et al. | Jun 2016 | B1 |
9387069 | Atkinson et al. | Jul 2016 | B2 |
9398949 | Werblin | Jul 2016 | B2 |
9421088 | Schieber et al. | Aug 2016 | B1 |
9427312 | Tai et al. | Aug 2016 | B2 |
9456895 | Shadduck et al. | Oct 2016 | B2 |
9486311 | Vaughan et al. | Nov 2016 | B2 |
9498326 | Tsai et al. | Nov 2016 | B2 |
9603703 | Bumbalough | Mar 2017 | B2 |
9622855 | Portney et al. | Apr 2017 | B2 |
9636213 | Brady | May 2017 | B2 |
9655775 | Boukhny et al. | May 2017 | B2 |
9681946 | Kahook et al. | Jun 2017 | B2 |
9693858 | Hildebrand et al. | Jul 2017 | B2 |
9744027 | Jansen | Aug 2017 | B2 |
9795473 | Smiley et al. | Oct 2017 | B2 |
9907881 | Terrisse | Mar 2018 | B2 |
1019501 | Salahieh et al. | Feb 2019 | A1 |
1035005 | Argento et al. | Jul 2019 | A1 |
1052635 | Silvestrini | Jan 2020 | A1 |
1054871 | Salahieh et al. | Feb 2020 | A1 |
10709549 | Argento et al. | Jul 2020 | B2 |
10736734 | Salahieh et al. | Aug 2020 | B2 |
20010037001 | Muller et al. | Nov 2001 | A1 |
20010056165 | Mentak et al. | Dec 2001 | A1 |
20020072795 | Green et al. | Jun 2002 | A1 |
20020086160 | Qiu et al. | Jul 2002 | A1 |
20020102415 | Valint, Jr. et al. | Aug 2002 | A1 |
20020103536 | Landreville et al. | Aug 2002 | A1 |
20020107568 | Zadno-Azizi et al. | Aug 2002 | A1 |
20020111678 | Zadno-Azizi et al. | Aug 2002 | A1 |
20020116057 | Ting et al. | Aug 2002 | A1 |
20020116058 | Zadno-Azizi et al. | Aug 2002 | A1 |
20020116059 | Zadno-Azizi et al. | Aug 2002 | A1 |
20020116060 | Nguyen et al. | Aug 2002 | A1 |
20020116061 | Zadno-Azizi et al. | Aug 2002 | A1 |
20020138141 | Zadno-Azizi et al. | Sep 2002 | A1 |
20020173847 | Pham et al. | Nov 2002 | A1 |
20020197414 | Chabrecek et al. | Dec 2002 | A1 |
20030008063 | Chabrecek et al. | Jan 2003 | A1 |
20030074060 | Zadno-Azizi et al. | Apr 2003 | A1 |
20030074061 | Pham et al. | Apr 2003 | A1 |
20030078656 | Nguyen | Apr 2003 | A1 |
20030078657 | Zadno-Azizi et al. | Apr 2003 | A1 |
20030078658 | Zadno-Azizi | Apr 2003 | A1 |
20030100666 | DeGroot et al. | May 2003 | A1 |
20030158560 | Portney | Aug 2003 | A1 |
20030162929 | Verbruggen et al. | Aug 2003 | A1 |
20030224185 | Valint, Jr. et al. | Dec 2003 | A1 |
20040111152 | Kelman et al. | Jun 2004 | A1 |
20040166232 | Kunzler et al. | Aug 2004 | A1 |
20040169816 | Esch | Sep 2004 | A1 |
20040184158 | Shadduck | Sep 2004 | A1 |
20040230300 | Bandhauer et al. | Nov 2004 | A1 |
20050013842 | Qiu et al. | Jan 2005 | A1 |
20050049700 | Zadno-Azizi et al. | Mar 2005 | A1 |
20050055092 | Nguyen et al. | Mar 2005 | A1 |
20050149183 | Shadduck et al. | Jul 2005 | A1 |
20050153055 | Ammon et al. | Jul 2005 | A1 |
20050165410 | Zadno-Azizi et al. | Jul 2005 | A1 |
20050228120 | Hughes et al. | Oct 2005 | A1 |
20050228401 | Zadno-Azizi et al. | Oct 2005 | A1 |
20060069432 | Tran | Mar 2006 | A1 |
20060100701 | Esch et al. | May 2006 | A1 |
20060100703 | Evans et al. | May 2006 | A1 |
20060116765 | Blake et al. | Jun 2006 | A1 |
20060178741 | Zadno-Azizi et al. | Aug 2006 | A1 |
20060241752 | Israel | Oct 2006 | A1 |
20060259139 | Zadno-Azizi et al. | Nov 2006 | A1 |
20060271187 | Zadno-Azizi et al. | Nov 2006 | A1 |
20070027540 | Zadno-Azizi et al. | Feb 2007 | A1 |
20070050025 | Nguyen et al. | Mar 2007 | A1 |
20070088433 | Esch et al. | Apr 2007 | A1 |
20070092830 | Lai et al. | Apr 2007 | A1 |
20070106377 | Smith et al. | May 2007 | A1 |
20070108643 | Zadno-Azizi et al. | May 2007 | A1 |
20070122540 | Salamone et al. | May 2007 | A1 |
20070201138 | Lo et al. | Aug 2007 | A1 |
20070203317 | Verbruggen et al. | Aug 2007 | A1 |
20070213817 | Esch et al. | Sep 2007 | A1 |
20070232755 | Matsushita et al. | Oct 2007 | A1 |
20070269488 | Ravi et al. | Nov 2007 | A1 |
20080001318 | Schorzman et al. | Jan 2008 | A1 |
20080003259 | Salamone et al. | Jan 2008 | A1 |
20080003261 | Schorzman et al. | Jan 2008 | A1 |
20080015689 | Esch et al. | Jan 2008 | A1 |
20080027461 | Vaquero et al. | Jan 2008 | A1 |
20080046074 | Smith et al. | Feb 2008 | A1 |
20080076897 | Kunzler et al. | Mar 2008 | A1 |
20080139769 | Iwamoto et al. | Jun 2008 | A1 |
20080143958 | Medina et al. | Jun 2008 | A1 |
20080181931 | Qiu et al. | Jul 2008 | A1 |
20080234457 | Zhou et al. | Sep 2008 | A1 |
20080300680 | Joshua et al. | Dec 2008 | A1 |
20080314767 | Lai et al. | Dec 2008 | A1 |
20090043384 | Niwa et al. | Feb 2009 | A1 |
20090118739 | Kappelhof et al. | May 2009 | A1 |
20090143499 | Chang et al. | Jun 2009 | A1 |
20090168012 | Linhardt et al. | Jul 2009 | A1 |
20090170976 | Huang et al. | Jul 2009 | A1 |
20090171459 | Linhardt et al. | Jul 2009 | A1 |
20090232871 | Hitz et al. | Sep 2009 | A1 |
20090247661 | Müller-Lierheim et al. | Oct 2009 | A1 |
20090292355 | Boyd et al. | Nov 2009 | A1 |
20100119744 | Yokoyama et al. | May 2010 | A1 |
20100120938 | Phelan et al. | May 2010 | A1 |
20100120939 | Phelan et al. | May 2010 | A1 |
20100121444 | Ben et al. | May 2010 | A1 |
20100160482 | Nachbaur et al. | Jun 2010 | A1 |
20100179653 | Argento et al. | Jul 2010 | A1 |
20100211170 | Liao et al. | Aug 2010 | A1 |
20100228346 | Esch et al. | Sep 2010 | A1 |
20100239633 | Strome et al. | Sep 2010 | A1 |
20100324674 | Brown et al. | Dec 2010 | A1 |
20110009519 | Awasthi et al. | Jan 2011 | A1 |
20110046332 | Breiner et al. | Feb 2011 | A1 |
20110118379 | Tighe et al. | May 2011 | A1 |
20110118834 | Lo et al. | May 2011 | A1 |
20110133350 | Qiu et al. | Jun 2011 | A1 |
20110140292 | Chang et al. | Jun 2011 | A1 |
20110144228 | Ravi et al. | Jun 2011 | A1 |
20110269869 | Medina et al. | Nov 2011 | A1 |
20110282442 | Scholl et al. | Nov 2011 | A1 |
20110295368 | Betser et al. | Dec 2011 | A1 |
20120010321 | Chang et al. | Jan 2012 | A1 |
20120023869 | Samuel et al. | Feb 2012 | A1 |
20120033183 | Dai et al. | Feb 2012 | A1 |
20120041097 | Zhou et al. | Feb 2012 | A1 |
20120046743 | Pinchuk et al. | Feb 2012 | A1 |
20120063000 | Batchko et al. | Mar 2012 | A1 |
20120078363 | Lu | Mar 2012 | A1 |
20120078364 | Stenger | Mar 2012 | A1 |
20120088843 | Chang et al. | Apr 2012 | A1 |
20120088844 | Kuyu et al. | Apr 2012 | A1 |
20120088861 | Huang et al. | Apr 2012 | A1 |
20120115979 | Chang et al. | May 2012 | A1 |
20120147323 | Domschke et al. | Jun 2012 | A1 |
20120238857 | Wong et al. | Sep 2012 | A1 |
20120245684 | Liao et al. | Sep 2012 | A1 |
20120314183 | Nakamura et al. | Dec 2012 | A1 |
20120330415 | Callahan et al. | Dec 2012 | A1 |
20130013060 | Zadno-Azizi et al. | Jan 2013 | A1 |
20130053954 | Rao et al. | Feb 2013 | A1 |
20130095235 | Bothe et al. | Apr 2013 | A1 |
20130106007 | Medina et al. | May 2013 | A1 |
20130110234 | DeVita et al. | May 2013 | A1 |
20130116781 | Ben et al. | May 2013 | A1 |
20130150961 | Evans et al. | Jun 2013 | A1 |
20130176628 | Batchko | Jul 2013 | A1 |
20130197125 | Awasthi et al. | Aug 2013 | A1 |
20130224309 | Qiu et al. | Aug 2013 | A1 |
20130228943 | Qiu et al. | Sep 2013 | A1 |
20130245756 | Liao et al. | Sep 2013 | A1 |
20130289294 | Awasthi et al. | Oct 2013 | A1 |
20130304203 | Beer | Nov 2013 | A1 |
20130317607 | DeBoer | Nov 2013 | A1 |
20140055750 | Dai et al. | Feb 2014 | A1 |
20140171539 | Chang et al. | Jun 2014 | A1 |
20140171542 | Chang | Jun 2014 | A1 |
20140178595 | Bothe et al. | Jun 2014 | A1 |
20140180403 | Silvestrini et al. | Jun 2014 | A1 |
20140180406 | Simpson | Jun 2014 | A1 |
20140180407 | Sohn et al. | Jun 2014 | A1 |
20141080406 | Simpson | Jun 2014 | |
20140228949 | Argento et al. | Aug 2014 | A1 |
20140277439 | Hu et al. | Sep 2014 | A1 |
20140309735 | Sohn et al. | Oct 2014 | A1 |
20140316521 | McLeod et al. | Oct 2014 | A1 |
20140350124 | Chang et al. | Nov 2014 | A1 |
20140379079 | Ben | Dec 2014 | A1 |
20150088149 | Auld | Mar 2015 | A1 |
20150092155 | Chang et al. | Apr 2015 | A1 |
20150105760 | Silvestrini et al. | Apr 2015 | A1 |
20150152228 | Chang et al. | Jun 2015 | A1 |
20150164321 | Weibel et al. | Jun 2015 | A1 |
20150177417 | Goshima et al. | Jun 2015 | A1 |
20150351901 | Chicevic et al. | Dec 2015 | A1 |
20160000558 | Honigsbaum et al. | Jan 2016 | A1 |
20160008126 | Vaughan et al. | Jan 2016 | A1 |
20160030161 | Rao et al. | Feb 2016 | A1 |
20160058553 | Salahieh et al. | Mar 2016 | A1 |
20160074154 | Woods | Mar 2016 | A1 |
20160100938 | Weeber et al. | Apr 2016 | A1 |
20160128826 | Rao et al. | May 2016 | A1 |
20160151150 | Sato | Jun 2016 | A1 |
20160184091 | Burns et al. | Jun 2016 | A1 |
20160184092 | Flaherty et al. | Jun 2016 | A1 |
20160250020 | Schieber et al. | Sep 2016 | A1 |
20160256265 | Borja et al. | Sep 2016 | A1 |
20160262875 | Smiley et al. | Sep 2016 | A1 |
20160278914 | Sato et al. | Sep 2016 | A1 |
20160296320 | Humayun et al. | Oct 2016 | A1 |
20160296662 | Dudic et al. | Oct 2016 | A1 |
20160317286 | Rao et al. | Nov 2016 | A1 |
20160317287 | Rao et al. | Nov 2016 | A1 |
20160331587 | Ueno et al. | Nov 2016 | A1 |
20170000602 | Sohn et al. | Jan 2017 | A1 |
20170020662 | Shadduck | Jan 2017 | A1 |
20170049561 | Smiley et al. | Feb 2017 | A1 |
20170049562 | Argento et al. | Feb 2017 | A1 |
20170119521 | Kahook et al. | May 2017 | A1 |
20170258581 | Borja et al. | Sep 2017 | A1 |
20170348094 | Sohn et al. | Dec 2017 | A1 |
20180110613 | Wortz et al. | Apr 2018 | A1 |
20180161152 | Argento et al. | Jun 2018 | A1 |
20180177589 | Argento et al. | Jun 2018 | A1 |
20190159890 | Salahieh et al. | May 2019 | A1 |
20190274823 | Argento et al. | Sep 2019 | A1 |
20200146813 | Argento et al. | May 2020 | A1 |
20200306031 | Salahieh et al. | Oct 2020 | A1 |
Number | Date | Country |
---|---|---|
2006200142 | Jul 2006 | AU |
2015361227 | Apr 2017 | AU |
2010203427 | May 2017 | AU |
2012335677 | Jun 2017 | AU |
2015258287 | Dec 2017 | AU |
2973684 | Jul 2016 | CA |
2974639 | Aug 2016 | CA |
2987311 | Dec 2016 | CA |
2752046 | Apr 2017 | CA |
2829143 | Apr 2017 | CA |
101351169 | Jun 2007 | CN |
102271623 | Jul 2010 | CN |
108472129 | Aug 2018 | CN |
0604369 | Jun 1994 | EP |
0734269 | Oct 1996 | EP |
0784652 | Jul 1997 | EP |
0800511 | Oct 1997 | EP |
0820601 | Jan 1998 | EP |
0826158 | Mar 1998 | EP |
0898972 | Mar 1999 | EP |
0907668 | Apr 1999 | EP |
0930357 | Jul 1999 | EP |
0604369 | Aug 1999 | EP |
0826158 | Sep 1999 | EP |
0947856 | Oct 1999 | EP |
0820601 | Dec 1999 | EP |
0800511 | Jan 2000 | EP |
0989138 | Mar 2000 | EP |
1084428 | Mar 2001 | EP |
1088246 | Apr 2001 | EP |
1090313 | Apr 2001 | EP |
1095711 | May 2001 | EP |
1095965 | May 2001 | EP |
1095966 | May 2001 | EP |
1109853 | Jun 2001 | EP |
0907668 | Sep 2001 | EP |
1141054 | Oct 2001 | EP |
1187873 | Mar 2002 | EP |
1200019 | May 2002 | EP |
1227773 | Aug 2002 | EP |
1230041 | Aug 2002 | EP |
1266246 | Dec 2002 | EP |
0898972 | Apr 2003 | EP |
1341485 | Sep 2003 | EP |
1364663 | Nov 2003 | EP |
1095711 | Jan 2004 | EP |
1141054 | Feb 2004 | EP |
1395302 | Mar 2004 | EP |
1410074 | Apr 2004 | EP |
1266246 | Jun 2004 | EP |
1109853 | Sep 2004 | EP |
1187873 | Sep 2004 | EP |
1084428 | Nov 2004 | EP |
1472305 | Nov 2004 | EP |
1230041 | Dec 2004 | EP |
0989138 | Feb 2005 | EP |
1095965 | Feb 2005 | EP |
1395302 | Feb 2005 | EP |
1507811 | Feb 2005 | EP |
1524953 | Apr 2005 | EP |
1200019 | Sep 2005 | EP |
1095966 | Jan 2006 | EP |
1660153 | May 2006 | EP |
1353611 | Sep 2006 | EP |
1696975 | Sep 2006 | EP |
1341485 | Nov 2006 | EP |
1723933 | Nov 2006 | EP |
1723934 | Nov 2006 | EP |
1750157 | Feb 2007 | EP |
1088246 | Nov 2007 | EP |
1857477 | Nov 2007 | EP |
1227773 | Jan 2008 | EP |
1888660 | Feb 2008 | EP |
1890650 | Feb 2008 | EP |
1902737 | Mar 2008 | EP |
1723933 | Nov 2008 | EP |
2035050 | Mar 2009 | EP |
2035480 | Mar 2009 | EP |
2035486 | Mar 2009 | EP |
1723934 | Jun 2009 | EP |
2066732 | Jun 2009 | EP |
2077292 | Jul 2009 | EP |
2092376 | Aug 2009 | EP |
1648534 | Sep 2009 | EP |
2094193 | Sep 2009 | EP |
2109784 | Oct 2009 | EP |
2120789 | Nov 2009 | EP |
2126614 | Dec 2009 | EP |
2035480 | Feb 2010 | EP |
2170708 | Apr 2010 | EP |
2185589 | May 2010 | EP |
2231207 | Sep 2010 | EP |
1750157 | Oct 2010 | EP |
2235094 | Oct 2010 | EP |
2276513 | Jan 2011 | EP |
2292672 | Mar 2011 | EP |
2356170 | Aug 2011 | EP |
2356497 | Aug 2011 | EP |
2109784 | Oct 2011 | EP |
2396355 | Dec 2011 | EP |
2035486 | Apr 2012 | EP |
2452212 | May 2012 | EP |
1857477 | Jun 2012 | EP |
1410074 | Oct 2012 | EP |
2092376 | Oct 2012 | EP |
2510051 | Oct 2012 | EP |
2513711 | Oct 2012 | EP |
2514791 | Oct 2012 | EP |
2356170 | Dec 2012 | EP |
2538266 | Dec 2012 | EP |
2563275 | Mar 2013 | EP |
2597113 | May 2013 | EP |
2598936 | Jun 2013 | EP |
2077292 | Aug 2013 | EP |
2625216 | Aug 2013 | EP |
2625217 | Aug 2013 | EP |
2625218 | Aug 2013 | EP |
2652532 | Oct 2013 | EP |
1830898 | Mar 2014 | EP |
2766750 | Aug 2014 | EP |
2452212 | Mar 2015 | EP |
2934383 | Oct 2015 | EP |
2200536 | Jan 2016 | EP |
2976042 | Jan 2016 | EP |
3185818 | Mar 2016 | EP |
2129331 | Apr 2016 | EP |
3003217 | Apr 2016 | EP |
3025678 | Jun 2016 | EP |
2259750 | Jul 2016 | EP |
2934383 | Jul 2016 | EP |
3062741 | Sep 2016 | EP |
3072476 | Sep 2016 | EP |
1999188 | Nov 2016 | EP |
2685935 | Nov 2016 | EP |
2094193 | Jan 2017 | EP |
2683287 | Feb 2017 | EP |
3062742 | Feb 2017 | EP |
3157466 | Apr 2017 | EP |
3160404 | May 2017 | EP |
3160683 | May 2017 | EP |
3049023 | Jun 2017 | EP |
3174500 | Jun 2017 | EP |
3181094 | Jun 2017 | EP |
2539351 | Jul 2017 | EP |
2283058 | Oct 2007 | ES |
2653325 | Apr 1991 | FR |
59-501897 | Nov 1984 | JP |
01-223970 | Sep 1989 | JP |
2006-518222 | Aug 2006 | JP |
2007-506516 | Mar 2007 | JP |
2007-517616 | Jul 2007 | JP |
2010-517639 | May 2010 | JP |
2012-532685 | Dec 2012 | JP |
9007545 | Jul 1990 | WO |
9007575 | Jul 1990 | WO |
9516475 | Jun 1995 | WO |
9611235 | Apr 1996 | WO |
9620919 | Jul 1996 | WO |
9631791 | Oct 1996 | WO |
9636890 | Nov 1996 | WO |
9749740 | Dec 1997 | WO |
9917684 | Apr 1999 | WO |
9929818 | Jun 1999 | WO |
9957581 | Nov 1999 | WO |
9960428 | Nov 1999 | WO |
9963366 | Dec 1999 | WO |
2000004078 | Jan 2000 | WO |
2000026980 | Jun 2000 | WO |
2000071613 | Nov 2000 | WO |
2001008607 | Feb 2001 | WO |
2001030512 | May 2001 | WO |
2001034067 | May 2001 | WO |
2001071392 | Sep 2001 | WO |
2002047583 | Jun 2002 | WO |
2002094331 | Nov 2002 | WO |
2003009014 | Jan 2003 | WO |
2003066707 | Aug 2003 | WO |
2003097711 | Nov 2003 | WO |
2004010905 | Feb 2004 | WO |
2004046768 | Jun 2004 | WO |
2004052242 | Jun 2004 | WO |
2004053536 | Jun 2004 | WO |
2004054471 | Jul 2004 | WO |
2004058318 | Jul 2004 | WO |
2004072689 | Aug 2004 | WO |
2005023331 | Mar 2005 | WO |
2005065734 | Jul 2005 | WO |
2006047383 | May 2006 | WO |
2006103674 | Oct 2006 | WO |
2006126095 | Nov 2006 | WO |
2007005778 | Jan 2007 | WO |
2007047529 | Apr 2007 | WO |
2007047530 | Apr 2007 | WO |
2007050394 | May 2007 | WO |
2007064594 | Jun 2007 | WO |
2008005644 | Jan 2008 | WO |
2008005652 | Jan 2008 | WO |
2008005752 | Jan 2008 | WO |
2008024766 | Feb 2008 | WO |
2008039655 | Apr 2008 | WO |
2008076729 | Jun 2008 | WO |
2008077040 | Jun 2008 | WO |
2008082957 | Jul 2008 | WO |
2008094876 | Aug 2008 | WO |
2008103798 | Aug 2008 | WO |
2008107882 | Sep 2008 | WO |
2008116132 | Sep 2008 | WO |
2008151088 | Dec 2008 | WO |
2009002703 | Dec 2008 | WO |
2009002789 | Dec 2008 | WO |
2009015161 | Jan 2009 | WO |
2009015226 | Jan 2009 | WO |
2009015234 | Jan 2009 | WO |
2009015240 | Jan 2009 | WO |
2009085755 | Jul 2009 | WO |
2009085756 | Jul 2009 | WO |
2009127844 | Oct 2009 | WO |
2010056686 | May 2010 | WO |
2010056687 | May 2010 | WO |
2010081093 | Jul 2010 | WO |
2010093823 | Aug 2010 | WO |
2011005937 | Jan 2011 | WO |
2011026068 | Mar 2011 | WO |
2011071790 | Jun 2011 | WO |
2011075377 | Jun 2011 | WO |
2011106435 | Sep 2011 | WO |
2012006616 | Jan 2012 | WO |
2012015639 | Feb 2012 | WO |
2012047961 | Apr 2012 | WO |
2012047964 | Apr 2012 | WO |
2012047969 | Apr 2012 | WO |
2012082704 | Jun 2012 | WO |
2012129407 | Sep 2012 | WO |
2012129419 | Sep 2012 | WO |
2013055746 | Apr 2013 | WO |
2013059195 | Apr 2013 | WO |
2013070924 | May 2013 | WO |
2013158942 | Oct 2013 | WO |
2013166068 | Nov 2013 | WO |
2014093751 | Jun 2014 | WO |
2014093764 | Jun 2014 | WO |
2014095690 | Jun 2014 | WO |
2014099630 | Jun 2014 | WO |
2014143926 | Sep 2014 | WO |
2014149462 | Sep 2014 | WO |
2014152017 | Sep 2014 | WO |
2015038620 | Mar 2015 | WO |
2015048279 | Apr 2015 | WO |
2015066502 | May 2015 | WO |
2015148673 | Oct 2015 | WO |
2016018932 | Feb 2016 | WO |
2016033217 | Mar 2016 | WO |
2016038470 | Mar 2016 | WO |
2016061233 | Apr 2016 | WO |
2016122805 | Aug 2016 | WO |
2016140708 | Sep 2016 | WO |
2016195095 | Dec 2016 | WO |
2016201351 | Dec 2016 | WO |
2017079449 | May 2017 | WO |
2017079733 | May 2017 | WO |
2017087358 | May 2017 | WO |
2017208230 | Dec 2017 | WO |
2017221196 | Dec 2017 | WO |
2017223544 | Dec 2017 | WO |
2018119408 | Jun 2018 | WO |
2018222579 | Dec 2018 | WO |
2018227014 | Dec 2018 | WO |
Entry |
---|
Klank, et al. “CO2-laser micromachining and back-end processing for rapid production of PMMA-based microfluidic systems,” Lab Chip, 2002, 2, 242-246, (Sep. 2002). |
Tsao, et al. “Bonding of thermoplastic polymer microfluidics. Microfluid Nanofuild,” 2009, 6:1-16, (published online: Nov. 13, 2008). |
Liang et al., “Bionic intraocular lens with variable focus and integrated structure,” Optical Engineering 2015, vol. 54, No. 10, Article No. 105106, Internal pp. 1-7, (Oct. 2015). |
International Search Report and Written Opinion received for PCT Application No. PCT/US18/34858, filed May 29, 2018; Applicant: Shifamed Holdings, LLC; dated Sep. 17, 2018, 9 pages. |
International Search Report and Written Opinion for PCT Application No. PCT/US2020/029131, filed Apr. 21, 2020, Applicant: Shifamed Holdings, LLC, dated Sep. 21, 2020, 15 pages. |
International Search Report and Written Opinion for PCT Application No. PCT/US2020/041644, filed Jul. 10, 2020, Applicant: Shifamed Holdings, LLC, dated Oct. 27, 2020, 11 pages. |
Umbrecht, et al. “Solvent assisted bonding of polymethylmethacrylate: characterization using the response surface methodology,” Jan. 2008, pp. 1325-1328. |
Number | Date | Country | |
---|---|---|---|
20200121447 A1 | Apr 2020 | US |
Number | Date | Country | |
---|---|---|---|
62512536 | May 2017 | US | |
62560527 | Sep 2017 | US |